Claims
- 1. A composition for alleviating acne scarring, comprising a compatible combination of: a non-retinoid inhibitor of a dermal matrix-degrading enzyme; and an active ingredient selected from the group consisting of comedolytics, antibacterials, anti-inflammatories, retinoids, glucocorticoids, and compatible mixtures thereof.
- 2. The composition of claim 1, wherein the inhibitor is an inhibitor is selected from the group consisting of AP-1 inhibitors, NF-κB inhibitors, elastase inhibitors, adhesion antagonists, and mixtures thereof.
- 3. The compositon of claim 1, wherein the composition is applied topically and is provided in combination with a dermatologically-acceptable carrier.
- 4. The compositon of claim 1, wherein the composition is administered systemically.
- 5. The composition of claim 1, wherein the active ingredient is a retinoid.
- 6. The composition of claim 1, wherein the active ingredient is an antibacterial.
- 7. The composition of claim 6, wherein the active ingredient is benzoyl peroxide.
- 8. The composition of claim 1, comprising a combination of an MMP inhibitor and a neutrophil elastase inhibitor.
- 9. The composition of claim 1, wherein the inhibitor is an antioxidant.
- 10. A method for treating acne, comprising the steps of: orally administering an active ingredient for the treatment of acne and topically administering a non-retinoid, non-glucocorticoid inhibitor of a dermal matrix degrading enzyme to acne-affected skin.
- 11. The method of claim 10, wherein the active ingredient is a retinoid or a tetracycline or derivative thereof.
- 12. The method of claim 10, wherein the inhibitor is selected from the group consisting of AP-1 inhibitors, NF-κB inhibitors, elastase inhibitors, selectin inhibitors, and compatible mixtures thereof.
- 13. The method of claim 12, wherein the inhibitor of a dermal matrix degrading enzyme is an MMP inhibitor.
- 14. The method of claim 10, wherein the inhibitor an antioxidant.
- 15. The method of claim 10, wherein the inhibitor is applied regularly from once every two days to twice daily.
- 16. The method of claim 15, wherein the inhibitor is applied daily.
- 17. The method of claim 10, wherein the inhibitor comprises a combination of an MMP inhibitor and an elastase inhibitor.
- 18. The method of claim 1, wherein the inhibitor is a direct MMP inhibitor.
- 19. The method of claim 1, wherein the inhibitor is an indirect MMP inhibitor.
- 20. A combined therapy for alleviating acne scarring, comprising a compatible combination of: a non-retinoid inhibitor or antagonist of an receptor sensitive to LPS-like material; and an active ingredient selected from the group consisting of comedolytics, antibacterials, anti-inflammatories, retinoids, glucocorticoids, non-retinoid MMP inhibitors, and compatible mixtures thereof.
- 21. The combined therapy of claim 20, wherein the composition is applied topically and is provided in combination with a dermatologically-acceptable carrier.
- 22. The combined therapy of claim 20, wherein at least one of the active ingredient and the inhibitor is administered topically.
- 23. The combined therapy of claim 20, wherein at least one of the active ingedient and the inhibitor is administered orally.
- 24. The combined therapy of claim 20, where the combination is provided as a single, topically applied composition.
- 25. The combined therapy of claim 20, wherein the inhibitor or antagonist inhibits or antagonizes a TLR.
- 26. A method for treating acne, comprising the steps of: administering an active ingredient for the treatment of acne and administering a non-retinoid, non-glucocorticoid inhibitor or antagonist of a receptor sensitive to LPS-like compounds induced or produced by P. acnes.
- 27. The method of claim 26, wherein the active ingredient is a retinoid or a tetracycline or derivative thereof.
- 28. The method of claim 26, wherein the inhibitor or antagonist is administered topically and applied regularly from once every two days to twice daily.
- 29. The method of claim 25, wherein the inhibitor or antagonist is administered daily and the active ingredient is administered topically.
- 30. The method of claim 26, wherein the inhibitor or antagonist reduces the induction or production or signalling by NF-κβ.
- 31. A method for treating acne, comprising administering a non-retinoid inhibitor of NF-κβ to a patient in need thereof.
- 32. The method of claim 31, wherein the inhibitor affects the production of NF-κβ from TLRs.
- 33. A method for treating acne, comprising administering an inhibitor that prevents CD-14 from activating toll-like receptors.
- 34. The method of claim 33, wherein the CD-14 inhibitor is administered topically.
Parent Case Info
[0001] This application is a CIP of application Ser. No. 09/576597, which is based on application Ser. No. 60/134984.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60134984 |
May 1999 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09576597 |
May 2000 |
US |
Child |
09852154 |
May 2001 |
US |